New Oral Anticoagulants in Coronary Artery Disease

Author(s): Michael Behnes, Christian Fastner, Uzair Ansari, Ibrahim Akin.

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Volume 15 , Issue 2 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


The implementation of therapeutic anticoagulation influences the severity and outcome of patients with coronary artery disease (CAD). This review aims to summarize the current guidelinebased recommendations about the use of new oral anticoagulants (NOACs) in patients with stable CAD (SCAD), acute coronary syndromes (ACS), percutaneous coronary interventions (PCI) and in patients with concomitant atrial fibrillation (AF). The implications of the use of specific NOACs, such as the direct factor Xa inhibitors apixaban and rivaroxaban as well as the direct thrombin inhibitor dabigatran are outlined and compared to the benefits of vitamin k antagonists and antiplatelet agents such as thienopyridines in these settings.

Keywords: Acute coronary syndrome, coronary artery disease, coumadin, novel oral anticoagulation, PCI, vitamin k antagonist, warfarin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [101 - 105]
Pages: 5
DOI: 10.2174/1871529X1502151209111429

Article Metrics

PDF: 114
PRC: 1